Prospects for IL-16 in the treatment of AIDS

Expert Opinion on Biological Therapy

Volumn 1, Issue 3, 2001, Pages 425-432

  Kornfeld, Hardy ^a   Cruikshank, William W ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AIDS; Antiviral therapy; HIV 1; Immune reconstitution; Interleukin 16

Indexed keywords

INTERLEUKIN 16;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HUMAN; REVIEW;

ACQUIRED IMMUNODEFICIENCY SYNDROME; HUMAN; INTERLEUKIN-16;

EID: 0035348162     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.1.3.425     Document Type: Article

References (59)

1. ANONYMOUS: Interleukin 16 (IL-16). A terminology note. IUIS/WHO Standing Committee on Interleukin Designation. / Immunol. Methods (1996) 196:103-104.
2. ANONYMOUS: Interleukin 16 (IL-16). IUIS/WHO Standing Committee on Interleukin Designation. Bulletin WHO (1996) 74:451-452.
3. CENTER DM, CRUIKSHANK WW: Modulation of lymphocyte migration by human h/mphokincs. I. Identification of characterization of chemoattractant activity for lymphoyctes from mitogcn-stimulated mononuclear cells./ Immunol. (1982) 128:2563-2568. • First description of the cytokine now called IL-16.
4. CRUIKSHANK WW, CENTER DM: Modulation of lymphocyte migration by human lymphokines. II. purification of a rymphotactic factor (LCF). / Immunol. (1982) 128:2569-2574.
5. KEANE J, NICOLL J, KIM S et al.: Conservation of structure and function between human and marine IL-16.J. Immunol. (1998) 160:5945-5954. • Describes the genetic and peptide structure of pro-IL-16, as well as the high degree of sequence homology and functional activities across mammalian species.
6. DAIER M, BANNERT N, WERNER A, LANG K, KURTH R: Molecular cloning, sequence, expression and processing of the interleukin 16 precursor. Proc. Nail. Acad. Sei. USA (1997) 94:5273-5277.
7. BANNERT N, ADLER HS, WERNER A, BAIER M, KURTH R: Molecular cloning and sequence analysis of interleukin 16 from nonhuman primates and from the mouse. Immunogenetics (1998) 47:390-397.
8. KÜRSCHNER C, YUZAKI M: Neuronal interleukin-l6 (NIL-16): a dual function PDZ domain protein. / Neurosci. (1999) 19:7770-7780.
9. ZHANG Y, CENTER DM, WU DM et al: Processing and activation of pro-interleukin-l6 by caspase-3. / Blol. Cbem. (1998) 273:1144-1149.
10. LABERGE S, CRUIKSHANK WW, KORNFELD H, CENTER DM: Histamine-induced secretion of lymphocyte chemoattractant factor from CDS T cells Is independent of transcription and translation. Evidence for constitutive protein synthesis and storage./ Immiinol. (1995) 155:2902-2910.
11. LABERGE S, CRUIKSHANK WW, BEER DJ, CENTER DM: Secretion of 1L-16 (lymphocyte chemoattractant factor) from serotonin- stimulated CDS T cells in vitro. J. Immunol. (1996) 156:310-315.
12. WU DMH, ZHANG Y, PARADA NA et al.: Processing and release of interleukin-l6 from CD4+ but not CDS T cells is activation dependent. J. Immunol. (1999) 162:1287-1293.
13. BERMANJS, CRUIKSHANK WW, CENTER DM, THEODORE AC, BEER DJ: Chemoattractant lymphokincs specific for the helper/inducer T-lymphocyte subset. Cell. Immunol. (1985) 95:105-112.
14. RAND TH, CRUIKSHANK WW, CENTER DM, WELLER PF: CD4-mediated stimulation of human cosinophils: lymphocyte chemoattractant factor and other CD4-binding ligands elicit eosinophil migration.J. Exp. Med. (1991) 173:1521-1528.
15. KÄSER A, DUNZENDORFER S, OFFNER FA et al.-. B lymphocyte-derived IL-16 attracts dendritic cells and Th cells./ Immunol. (2000) 165:2474-2480.
16. CRUIKSHANK WW, CENTER DM, NISAR N et al.: Molecular and functional analysis of a lymphocyte chemoattractant factor: association of biologic function with CD4 expression. Proc. Natl.Acad. Sei. USA (1994) 91:5109-5113.
17. PARADA NA, CENTER DM, KORNFELD H et al.: Synergistic activation of CD4 T cells by IL-16 and JL-2. J. Immunol. (1998) 160:2115-2120. •• Key in vitro rodata indicating the potential forIL-16 in immune reconstitution. Cultures of PBMC could be expanded continuously by co-treatment with IL-16 and IL-2 in contrast to cultures treated with either cytokine alone.
18. CRUIKSHANK WW, BERMAN JS, THEODORE AC, BERNARDO J, CENTER DM: Lymphokine activation of T4 lymphocytes and monocytes. / Immunol. (1987) 138:3817-3823.
19. BANK I, CHESS L: Perturbation of the T4 molecule transmits a negative signal to T cells./ Exp. Med. (1985) 162:1294-1303-
20. BIDDISON WE, RAO PE, TALLE MA, GOLDSTEIN G, SHAW S: Possible involvement of the OKT4 molecule in T cell recognition of class IIH1A antigens.J. Exp. Med. (1982) 156:1065-1076.
21. OYAIZU N, CHIRMULE N, KALYANARAMAN VS, HALL WW, GOOD RA, PAHWA S: Human immunodeficiency virus Type 1 envelope glycoprotein gp!20 produces immune defects in CD4 T lymphocytes by inhibiting interleukln 2 mRNA. Proc. Natl. Acad. Sei. USA (1990) 87:2379-2383-
22. CRUIKSHANK WW, LIM K, THEODORE AC et al.-. IL-16 inhibition of CD3-depcndent lymphocyte activation and proliferation. / Immunol. (1996) 157:5240-5248.
23. THEODORE AC, CENTER DM, NICOLL J, FINE G, KORNFELD H, CRUIKSHANK \V\V: CD4 ligand IL-16 inhibits the mixed lymphocyte reaction. / Immunol. (1996) 157:1958-1964.
24. NICOLL J, CRUIKSHANK \VW, BRAZER \V, LIU Y, CENTER DM, KORNFELD H: Identification of domains in IL-16 critical for biological activity. J. Immunol. (1999) 163:1827-1832. •• This is the first published structure-function analysis of IL-16 using point mutations and deletions to assess the requirements for the biological activities of chemotaxis and MLR inhibition. A single point mutation in the C-terminal tail abolishes chemoattractant activity, while deletion of both die N-terminal and C-terminal tails is needed to completely abolish MLR inhibitory activity.
25. MATHY NL, BANNERT N, NORLEY SG, KURTH R: Cutting edge: CD4 is not required for the functional activity of JL-16.J. Immunol. (2000) 164:4429-4432.
26. STOITZNER P, RATZINGER G, KOCH F et al.: Interleukin-l6 supports the migration of Langerhans cells, partly in a CD4-indedpcndcnt way. J. Invest. Dermatol. (2001) In press.
27. CENTER DM, KORNFELD H, CRUIKSHANK WW: Intcrlcukin 16 and its function as a CD4 ligand. Immunol. Today (1996) 17:476-481.
28. RYAN TC, CRUIKSHANK WW, KORNFELD H, COLLINS TL, CENTER DM: The CD4-associatcd tyrosine kinase p561ck is required for lymphocyte chemoattractant factor-induced T lymphocyte migration. J. Biol. Chem. (1995) 270:17081-17086.
29. LIU Y, CRUIKSHANK WW, O'LOUGHLIN T, O'REILLY P, CENTER DM, KORNFELD H: Identification of a CD4 domain required for IL-16 binding and lymphocyte activation./ Biol. Chem. (1999) 274:23387-23395. • Describes the binding site on CD4 for IL-16, showing that it overlaps the areas previously determined to lie at the interface of CD4 homodimers.
30. CRUIKSHANK WW, GREENSTEIN JL, THEODORE AC, CENTER DM: Lymphocyte chemoattractant factor induces CD4-dependent intracytoplasmic signaling in lymphocytes.J. Immunol. (1991) 146:2928-2934.
31. WU H, KWONG PD, HENDRICKSON WA: Dimeric association and segmental variability in the structure of human CD4. Nature (1997) 387:527-530.
32. SATOH T, LI S, FRIEDMAN TM, WIADERKIEWICZ R, KORNGOLD R, HUANG Z: Synthetic peptides derived from the fourth domain of CD4 antagonize off function and inhibit T cell activation. Biocbem. Biopbys. Res. Com. (1996) 224:438-443.
33. MASHIKIAN MV, RYAN TC, SEMAN A, BRAZER W, CENTER DM, CRUIKSHANK WW: Reciprocal desensitization of CCR5 and CD4 is mediated by IL-16 and macrophageinflammatory protein-1 beta, respectively.J. Immunol. (1999) 163:3123-3130.
34. VAN DRENTH C, JENKINS A, LEDWICH L étal.: Desensitization of CXC chemokinc receptor 4, mediated by IL-16/CD4, is independent of p56(lck) enzymatic activity.J. Immunol. (2000) 165:6356-6363.
35. MUHLHAHN P, ZWECKSTETTER M, GEORGESCU J étal: Structure of interleukln 16 resembles a PDZ domain with an occluded peptidc binding site. Nat. Stniclur. Biol. (1998) 5:682-686. • NMR structure of IL-16, showing its conformation is that of a PDZ domain.
36. WALKER CM, MOODY DJ, STITES DP, LEVY JA: CDS lymphocytes can control HIV infection in vitro by suppressing virus replication. Science (1986) 234:1563-1566.
37. WALKER CM, ERICKSON AL, HSUEH EC, LEVY JA: Inhibition of human immunodeficiency virus replication in acutely infected CD4 cells by CDS cells involves a noncytotoxic mechanism./ Virol. (1991) 65:5921-5927.
38. BRINCHMANN JE, GAUDERNACK G, VARTDAL F: CDS T cells inhibit HIV replication in naturally infected CD i T cells. Evidence for a soluble inhibitor. J. Immunol. (1990) 144:2961-2966.
39. CHEN C-H, WEINHOLD KJ, BARTLETT JA, BOLOGNESI DP, GREENBERG ML: CDS T lymphocyte-mediated inhibition of HIV-1 long terminal repeat transcription: a novel antiviral mechanism. AIDS Res. Human Retrovir. (1993) 9:1079-1086.
40. ENNEN J, FINDEKLEE H, DITTMAR MT, NORLEY S, ERNST M, KURTH R: CDS T lymphocytes of African green monkeys secrete an immunodeficiency virussuppressing lymphokinc. Proc. Natl. Acad. Sei. USA (1994) 91:7207-7211.
41. BAIER M, WERNER A, BANNERT N, METZNER K, KURTH R: HIV suppression by interleukin-16. Nature (1995) 378:563. •First description of antiviral activity by IL-16.
42. IDZIOREK T, KHALIFE J, BILLAUT-MULOT O et a!.: Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD). Clin. Exp. Immunol. (1998) 112:84-91. •• Evidence that HIV-1 repression is mediated by the homotetrameric form of IL-16. This paper also describes the capacity of IL-16 to inhibit AICD, an activity that may be important for immune reconstitution.
43. ZHOU P, GOLDSTEIN S, DEVADAS K, TEWARI D, NOTK1NS AL: Human CD4 cells transfected with IL-16 cDNA are resistant to HIV-1 infection: inhibition of mRNA expression. Nat. Med. (1997) 3:659-664. •• First description of IL-16 in a gene therapy model.
44. ZHOU P, DEVADAS K, TEWARI D, JEGOROW A, NOTKINS AL: Processing, secretion and anti-HIV-1 activity of IL-16 with or without a signal peptide in CD4 T cells./ Immunol. (1999) 163:906-912.
45. LEE ME, ADAMS JW, VILLINGER F et al.: Molecular cloning and expression of rhesus macaque and sooty mangabey interleukin 16: biologic activity and effect on simian immunodeficiency virus infection and/or : replication. AIDS Res. Hum. Relroviruses (1998) 14:1323-1328.
46. LEUTENEGGER CM, HUDER JB, MISLIN CN et al: Molecular characterization of feline intcrlcukin 16: chemotactic activity and effect on feline immunodeficiency virus infection and/or replication. AIDS Res. Hum. Ketrovinises (2000) 16:569-575.
47. MERTENS B, BISHOP R, TARACHA E, MORZARIA S, NENE V, SAVADYE D: Cloning, sequence and mRNA expression of bovine interleukin-16. DMA Seq. (2000) 10:425-428.
48. MACIASZEK J\V, PARADA NA, CRUIKSHANK WW, CENTER DM, KORNFELD H, VIGLIANTI GA: IL-16 represses HIV-1 promoter activity. J Jmmunol. (1997) 158:5-8.
49. TRUONG MJ, DARCISSAC EC, HERMANN E, DEWULF J, CAPRON A, BAHR GM: Interlcukin-l6 inhibits human immunodeficiency virus Type 1 entry and replication in macrophages and in dendritic cells. J. Virol. (1999) 73:7008-7013. •• First report that IL-16 inhibits HIV-1 in monocytic cells at the level of viral entry.
50. MCKENZIE SW, DALLALIO G, NORTH M, FRAME P, MEANS RT: Scrum chemokinc levels in patients with non-progressing HIV infection. .4/05(1996) 10:F29-F33.
51. BISSET LR, ROTHEN M, JOLLER-JEMELKA HI, DUBS RW, GROB PJ, OPRAVIL M: Change in circulating levels of the chemokines macrophage inflammatory proteins 1 alpha and 11 beta, RANTES, monocytc chcmotactic protein-1 and intcrlcukin-16 following treatment of severely immune-deficient HIV-infected individuals with indinavir. ,1/05(1997) 11:485-491. •• A clinical study finding that indinavir treatment is associated with dramatically increased serum levels of IL-16, in contrast to modest changes in -chemokine levels.
52. AMIEL C, DARCISSAC E, TRUONG M-J et al.: Interleukin-16 (IL-16) inhibits human immunodefiency virus replication in cells from infected subjects and serum IH6 levels drop with disease progression. J. Infect. Dis. (1999) 179:83-91. •This paper links reduced serum IL-16 levels to disease progression in HIV/AIDS.
53. SCALA E, D'OFFIZI G, ROSSO R et al.-. C-C chemokînes, 1L-16 and soluble antiviral factor activity arc increased in cloned T cells from subjects with long-term nonprogressive HIV infection. J. Immnnol. (1997) 158:4485-4492.
54. SHARKEYME, TEO I, GREENOUGHTe/oJ.: Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy. Nat. Med. (2000) 6:76-81.
55. SZABO P, ZHAO K, KIRMAN I et al: Maturation of B cell precursors Is impaired in thymic-dcprived nude and old mice./ Immitnol. (1998) 161:2248-2253.
56. DE BIE JJ, JONKER EH, HENRICKS PAJ, CRUIKSHANK WW, NIJKAMP FP, VAN OOSTERHOUT AJM: IL16 inhibits both antigen-Induced allergic airway symptoms and Tn2-type cytokine production in mice. Submitted.
57. SERET11, GEA-BANACLOCHE J, KAN MY, HALLAHAN CW, LANE HC: Interleukin-2 leads to dose-dependent expression of the alpha chain of the IL-2 receptor on CD25-negative T lymphocytes in the absence of exogenous antigcnic stimulation. Clin. Immunol. (2000) 97:266-276.
58. KHATRIVP, FEHNIGER TA, BAIOCCHIRA et al: Ultra low dose intcrlcukin-2 therapy promotes a Type 1 cytokine profile in vivo in patients with AIDS and AIDS-associated malignancies. J. Clin. Invest. (1998) 101:1373-1378.
59. DE PAOLI P, ZANUSSI S, SIMONELLI C et al: Effects of subcutaneous interleukin-2 therapy on CD4 subsets and in vitro cytokine production in HIV+ subjects. / din. Invest. (1997) 100:2737-2743.